[A24-76] Gozetotide (positron emission tomography, prostate cancer [mCRPC]) – Benefit assessment according to § 35a Social Code Book V
Last updated 15.10.2024
Project no.:
A24-76
Commission:
Commission awarded on 15.07.2024 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Diagnostics
Adults with progressive metastatic castration resistant prostate cancer (mCRPC): identification of patients with prostate-specific membrane antigen-positive mCRPC for whom prostate-specific membrane antigen-targeted therapy is indicated
- Patients for whom abiraterone in combination with prednisone or prednisolone, enzalutamide or BSC is the individually optimized treatment: indication of major added benefit
- Patients for whom cabazitaxel or olaparib is the individually optimized treatment: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://dx.doi.org/10.60584/A24-76